Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.QRxPharma has announced that a number of patients have been treated in the first of several clinical studies to be conducted as part of the double-blind, placebo-controlled Phase III development program for its lead product candidate Q8003IR, an immediate release dual-opioid pain therapy.
Subscribe to our email newsletter
This initial clinical trial is designed to compare the efficacy and safety of four different dosage strengths of Q8003IR versus placebo in a post-surgery, acute pain setting. The study is being conducted at eight US clinical research sites and is targeted to enroll 250 patients experiencing moderate to severe pain following a scheduled surgical procedure (bunionectomy).
John Holaday, managing director and CEO of QRxPharma, said: “Initiation of this Phase III clinical trial program not only demonstrates the company’s ability to deliver on its development milestones for Q8003IR in terms of budget and time-line projections, but also represents a significant step forward towards our goal of commercializing our first dual-opioid pain therapy in 2010.”